New draft guidance from the US Food and Drug Administration would mandate that patients considering Laser-Assisted in Situ Keratomileusis (LASIK) get additional information about potential risks of the popular vision-correcting treatment.
The agency hopes that the 28 July guidance will help ensure that patients and health care providers can access clear information about the benefits and risks of LASIK treatment, including potential adverse events such as dry eye, pain, discomfort, and visual symptoms